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The ability of human pluripotent stem cells to diﬀerentiate towards the cardiac lineage has attracted significant interest, initially
with a strong focus on regenerative medicine. The ultimate goal to repair the heart by cardiomyocyte replacement has, however,
proven challenging. Human cardiac diﬀerentiation has been diﬃcult to control, but methods are improving, and the process,
to a certain extent, can be manipulated and directed. The stem cell-derived cardiomyocytes described to date exhibit rather
immature functional and structural characteristics compared to adult cardiomyocytes. Thus, a future challenge will be to develop
strategies to reach a higher degree of cardiomyocyte maturation in vitro, to isolate cardiomyocytes from the heterogeneous pool of
diﬀerentiating cells, as well as to guide the diﬀerentiation into the desired subtype, that is, ventricular, atrial, and pacemaker cells. In
this paper, we will discuss the strategies for the generation of cardiomyocytes from pluripotent stem cells and their characteristics,
as well as highlight some applications for the cells.
1. Introduction
Human cardiomyocytes can be isolated from heart biopsies,
but the access to human heart tissue is very limited, and
the procedure is complicated; it is diﬃcult to obtain viable
cell preparations in large quantities, and the cells obtained
do not beat spontaneously. Thus, physiologically relevant
in vitro models for human cardiomyocytes are currently
limited. This has led in the creation of alternative models,
such as isolation of cardiomyocytes from various newborn
animals or production of genetically engineered cell lines
overexpressing certain target proteins (e.g., ion channels) [1].
All of these models, however, share significant limitations
with respect to their basic physiological diﬀerences compared
to human cardiomyocytes as well as high costs and ethical
questions. A number of diﬀerent human tissues have been
proposed as the source of stem cells able to generate new
cardiomyocytes (e.g., fetal cardiomyocytes, adult cardiac
progenitor cells, skeletal myoblasts, bone marrow-derived
stem cells, adipose-derived stem cells, umbilical cord-derived
stem cells, and pluripotent stem cells) [2]. The cardiac
diﬀerentiation potential of adult, multipotent, stem cells
found in fetal and adult tissues, however, is controversial
[3, 4]. This has been attributed to the limited plasticity
of adult stem cells, which precludes their diﬀerentiation
into functional cardiomyocytes. The only adult stem cells
that clearly have the potential to diﬀerentiate into beating
cardiomyocytes are cardiac progenitor cells [5]. In addition,
so far, only pluripotent stem cells have been shown in vitro
to eﬃciently diﬀerentiate into spontaneously contracting
cardiomyocyte-like cells [6–9].
Pluripotent stem cells have nearly unlimited self-renewal
capability in vitro and have the ability to diﬀerentiate
into all three germ layers and thus, in principle, can give
rise to all cell types of the human body [10]. Since the
first description of the isolation and characterization of
human embryonic stem cells (hESCs) from donor blastocysts
[11], there have been reports of diﬀerentiation of hESCs
to functional cardiomyocytes by multiple diﬀerentiation
methods. Recent breakthroughs in the field of induced
pluripotent stem (iPS) cell technology have demonstrated
that human iPS cells may provide an additional source for
in vitro diﬀerentiated cardiomyocytes, sharing similarities
with their hESC-derived counterparts [12–14]. Currently,
cardiomyocytes can be diﬀerentiated from pluripotent stem
cells by (1) spontaneous embryoid body (EB) diﬀerentiation
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in suspension, (2) coculture with mouse endoderm-like cells
(END-2 cells), or (3) guiding the cardiac diﬀerentiation with
defined growth factors either in suspension or in monolayer
culture [15].
Owing to the cardiac phenotype and the functional prop-
erties of the pluripotent stem cell-derived cardiomyocytes,
they can oﬀer more physiologically and clinically relevant
reproducible human cell models than presently available.
In vitro diﬀerentiated cardiomyocytes may serve as models
to study early events of human cardiogenesis and have the
potential to be used in pharmaceutical drug discovery and
safety toxicology. Animal models currently widely used in
drug metabolism and toxicity studies are not fully reliable
predictors of human responses because of basic physiological
diﬀerences between species such as remarkably faster beating
rate of the mouse may override the eﬀects of arrhyth-
mias which would be severe for human. It is anticipated
that pluripotent stem cell-derived cardiomyocytes will be
important in vitro tools for drug safety test which may
drastically facilitate drug development and generation of
safer drugs. In the field of cardiac regenerative repair, stem
cell-derived cardiomyocytes would facilitate the discovery
of small molecules promoting cardiomyocyte diﬀerentiation
to be used for the activation of endogenous cardiac stem
cells in clinical settings [15]. There is an urgent need
to standardize and validate assays involving pluripotent
stem cell-derived cardiomyocytes as well as to compare
these cardiomyocytes with established in vitro and in vivo
models in order to eﬀectively determine the capabilities and
limitations of the newmodels inmaking accurate predictions
of the cardiac safety profile of new potential drugs during the
development [15, 16]. The ability to reprogram adult cells
to pluripotent stem cells and to genetically manipulate stem
cells presents opportunities to develop models of human
diseases [17, 18]. Until today, many severe diseases have been
studied in animal models, particularly using transgenic mice.
Although mouse models can provide valuable information,
diﬀerences between human and mouse physiology limit the
applicability of the results. iPS cells derived from patients
suﬀering from various cardiac diseases or disorders, such
as channelopathies or congenital heart disease [19, 20],
are anticipated to become important tools for studying
the mechanisms underlaying the disease pathogenesis and
investigations of new treatment opportunities. However, it
remains to be demonstrated that in vitro generated patient-
specific iPS cell-derived cardiomyocytes actually recapitulate
the appropriate disease phenotype observed in the adult
heart.
Adult human cardiomyocytes are considered terminally
diﬀerentiated cells. Although a small percentage of the
cardiomyocytes may have proliferation capacity, it is not
suﬃcient to replace injured or dead cardiomyocytes, for
example, following myocardial injury. In recent years, the
stem cell technology has raised hopes for new treatments
for cardiac tissue damage with limited regenerative capac-
ity. The possibility to apply pluripotent stem cell-derived
cardiomyocytes to repair damaged myocardium has been
demonstrated in preclinical studies to be a feasible approach
although many hurdles remain to be solved before these
developments can be translated to the clinic [21–28]. In
brief, the obstacles to be solved include the generation of
purified cell preparations that eliminate the risk of teratoma
formation, defining the optimal timing for cell transplan-
tation after myocardial infarction, the appropriate level of
maturation of the cell preparation, dose and mechanism of
delivery to facilitate successful engraftment, minimizing graft
cell death following transplantation, and avoiding immune
rejection of the graft [16]. Additionally, concerns remain
that currently available pluripotent stem cell-derived car-
diomyocyte preparations includemyocytes with nodal, atrial,
and ventricular type of action potential (AP) properties
[8, 9]. This electrophysiological heterogeneity represents
both an opportunity and a challenge to the application
of stem cell-derived cardiomyocytes to cardiac repair. An
enriched preparation of nodal cells would be of potential
use in the formation of a biological pacemaker [29]. On
the other hand, nodal cells would be needed to exclude
from cardiomyocyte preparations for infarct repair, as their
sustained pacemaking activity and unique neurohormonal
responsivity could exacerbate the already elevated risk of
arrhythmias [30].
Eﬃcient methods to induce diﬀerentiation to cardiomy-
ocytes that generate homogenous populations of cardiomy-
ocytes of adequate quality, reproducibly, and in large
quantities are a prerequisite for any of these applications.
Future cell therapies will also require defined cardiomyocyte
production protocols fulfilling the regulatory requirements.
In this paper, we describe the developmental progression
from a pluripotent stem cell state to cardiomyocyte and
provide an overview of protocols for cardiac diﬀerentiation
of pluripotent stem cells as well as enrichment strategies of
cardiomyocytes so far available.
2. Lessons from Heart Development
The earliest events of organogenesis during embryonic
development are the formation of the heart. Although
the knowledge regarding the molecular mechanisms that
govern cardiogenesis in humans is still in its infancy,
experimental animal models have been of great value for
identifying various molecular events and a number of key
regulators operating under the diﬀerent stages of the early
cell commitment process during cardiogenesis. Studies in
mice and chick embryos have demonstrated that the heart
tissue is composed of three major mesoderm-derived cell
lineages: the cardiac myocyte, the vascular smooth muscle,
and the endothelial cell lineages. Soon after gastrulation,
a few days after fertilization, the three embryonic layers
form, the endoderm, the ectoderm, and the mesoderm. The
primitive streak is formed from primitive endoderm and is
the origin of many tissues. Cardiac progenitors form in the
posterior primitive streak [31]. Four main steps are required
to generate cardiomyocytes from pluripotent stem cells: (1)
formation of mesoderm, (2) the patterning of mesoderm
toward anterior mesoderm or cardiogenic mesoderm, (3)
formation of cardiac mesoderm, and (4) maturation of
early cardiomyocytes. The induction of pluripotent stem
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Figure 1: Diagram depicting sequential steps required for obtaining cardiomyocytes from pluripotent stem cells. Early mesoderm
diﬀerentiates via cardiac mesoderm and committed cardiac progenitors further to functional beating cardiomyocytes. Typical markers for
each step are indicated.
cell diﬀerentiation to cardiac fate following these steps can
be characterized by the expression of transcription factors,
such as T/Brachyury for primitive streak mesoderm, Mesp-
1 for cardiogenic mesoderm, and Nkx2.5, Tbx5/20, Gata-
4, Mef2c, and Hand1/2 for cardiac mesoderm [32–36].
Mesp-1 is thought to induce an epithelial-mesenchyme
transition in the epiblast and to bind directly to regulatory
DNA sequences in the promoters of many members of the
core cardiac regulatory network, including Nkx2.5 thereby
promoting development of mesoderm precursors of the
cardiovascular lineage as well as repressing the expression
of key genes regulating other early mesoderm derivatives
[37, 38]. Maturing cardiomyocytes can be identified by the
expression of cardiac structural proteins such as α-actinin,
α-myosin heavy chain (α-MHC), or the cardiac isoform of
Troponin-T (cTnT). By initiating the complex myocardial
cross-regulatory network, these factors are believed to be
involved in morphogenic events leading to the formation
of the heart. Figure 1 illustrates various steps in the diﬀer-
entiation of pluripotent stem cells to cardiomyocytes and
indicates the possible cell populations that may be available
for isolation and expansion.
Cardiac development is a dynamic process that is tightly
orchestrated by the sequential expression of multiple signal
transduction proteins and transcription factors working in a
combinatory manner. A number of signaling pathways and
growth factors have been implicated in the development of
specialized cardiac subtypes, and among themost studied are
Wnts/Nodal, BMPs, and FGFs [39–42]. Since these factors
work optimally during certain time window and, in some
instances, antagonize cardiogenesis during other windows,
the timing of the addition to guide the pluripotent stem
cells in the desired diﬀerentiation direction must be carefully
optimized.
In addition, microRNAs (mir) have been recently iden-
tified as major contributors to the diﬀerentiation process
[43, 44]. MicroRNAs are 22-23 nt long ssRNA involved
in gene regulation and capable of inhibiting initiation of
translation and inducing mRNA degradation. The heart
expresses miR-1, miR-133, miR-206, and specifically miR-
208 [45, 46]. Furthermore, miR-143 and -145 also appear
important for cardiomyogenesis [47]. A recent study investi-
gated expression of miR-1 andmiR-133 inmESCs and hESCs
and compared their potential to induce Nkx2.5 in embryoid
bodies and their influence on mesodermal diﬀerentiation.
miR-1 increased the proportion of beating aggregates and
thus appears to greatly enhance cardiac phenotype. On
the contrary, miR-133 promotes also early mesoderm dif-
ferentiation but inhibits further cardiac commitment [48].
Interestingly, both of these miRs are coexpressed from the
same cluster [49]. Identification of miRs regulating the
cardiac diﬀerentiation will oﬀer another route for guiding the
diﬀerentiation of cardiomyocytes.
The first step (i.e., mesoderm induction) in cardiac
diﬀerentiation from pluripotent stem cells has been well
characterized. Numerous studies have demonstrated that
Wnts, BMPs, and transforming growth factor (TGF) β-
family member Nodal (or Activin A as a substitute of Nodal)
eﬃciently induce mesoderm [50, 51]. Although some of the
mechanisms that control for the next two steps in cardiac
diﬀerentiation (i.e., patterning to cardiogenic mesoderm and
the formation of cardiac mesoderm) have been characterized
in experimental animal embryos, knowledge about how
these mechanisms might be applied to pluripotent stem cell
cardiogenesis is still lacking. Nodal and Wnt inhibition have
been found to regulate the formation of cardiomyocytes
in xenopus and chick embryos [52–54] and seem to be
important for mouse ESC diﬀerentiation to cardiomyocytes
[55, 56]. Dickkopf-1 (Dkk-1) is often employed as a Wnt
antagonist at this stage of diﬀerentiation protocols [57].
Another important signaling pathway is mediated by the
transmembrane receptor Notch, which has been shown
to induce the expression of a combination of the growth
factors Wnt5a, BMP6, and Sfrp1, which increase the amount
of cardiac progenitors form an ESC-derived mesoderm
subpopulation [58]. The last step in the diﬀerentiation stages
to cardiomyocytes is the diﬀerentiation of committed cardiac
progenitors to beating cardiomyocytes, a process that often
occurs spontaneously in vitro and is poorly understood but
might be controlled by factors such as Wnt11 [56]. Taken
together, very little is known about the two crucial steps in
cardiogenesis from pluripotent stem cells that is, promotion
of mesendoderm to form committed cardiac mesoderm and
factors to give rise to cardiomyocytes.
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Table 1: Summary of prevalent cardiac diﬀerentiation methods.
Method description
Diﬀerentiation
eﬃciency %
Stem cell type Reference
Spontaneous embryoid body method <10%
hESC
hiPSC
Kehat et al. [6]
Zhang et al. [12]
END-2 method
Insulin depletion, PGI2, p38 MAPK inhibition
20%–25%
hESC
hiPSC
Passier et al. [68], Graichen et al. [71]
Freund et al. [70]
Guided diﬀerentiation method
Activin A, BMP4
>30%
hESC
hiPSC
Laflamme et al. [27]
Takahashi et al. [17]
Guided diﬀerentiation method
Activin A, BMP4, bFGF, VEGF, Dkk-1
40%–50% hESC Yang et al. [57]
Spontaneous EB-diﬀerentiation
Suspension culture
of EBs
EBs plated on to
coated surface
END-2 diﬀerentiation -Serum
-Insulin
+MAPK inhibitor
+PGI2
Freeder-free culture on matrigel
Suspension culture of EBs
Pluripotent
stem cells
Direct cardiac diﬀerentiation
Coculture
or
END-2-CM
Growth factors
BMP2
BMP4
Activin A
bFGF
Wnt3a etc.
Figure 2: Schematic overview outlining diﬀerentiation approaches currently used for cardiomyocyte diﬀerentiation from pluripotent stem
cells. The embryoid body approach has, thus far, been the most utilized way to obtain beating cardiomyocytes from pluripotent stem cells
and the formation of three-dimensional cell aggregates initiates and facilitates the diﬀerentiation process. Generally, cells are transferred
to suspension cultures, or in order to obtain more stable and reproducible cell aggregates, the embryoid bodies are formed using the
hanging-drop or the forced aggregation method. Using the END-2 approach, cardiomyocyte diﬀerentiation is triggered either by coculture
of pluripotent stem cells, with END-2 cells or by embryoid body formation in suspension culture using END-2 conditioned medium. The
depletion of serum and insulin has been shown to facilitate cardiogenesis in this approach, and it can be further enhanced by inhibiting
p38 MAPK pathway by a specific inhibitor or by adding prostaglandin I2. In the guided diﬀerentiation approach, undiﬀerentiated pluripotent
stem cells are cultured under feeder cell-free conditions or in suspension culture after embryoid body formation. Cardiac diﬀerentiation is
induced with various growth factors, such as BMP2, BMP4, Activin A, bFGF, and Wnt3a.
3. Cardiac Differentiation of Pluripotent
Stem Cells
Table 1 and Figure 2 summarizes the diﬀerentiation ap-
proaches currently used for cardiomyocyte diﬀerentiation
from pluripotent stem cells.
3.1. Embryoid Body Formation and Spontaneous Cardiomyo-
cyte Diﬀerentiation. The initial observation that hESCs could
mature into spontaneously contracting cardiomyocyte-like
cells was reported ten years ago when hESCs were cultured
in suspension and formed three-dimensional aggregates
called embryoid bodies [6, 59]. Within the embryoid body,
derivatives of the three germ layers (ectoderm, endoderm,
and mesoderm) develop spontaneously. Within these mixed
population of cells contracting areas with functional prop-
erties of cardiomyocytes can be detected. Cardiomyocytes
are one of the first cell types induced from pluripotent
stem cells in embryoid bodies, where cell to cell interactions
stimulate the expression of markers for mesodermal and
early cardiac cell lineages [60]. Typically, the embryoid
bodies are plated on a matrix-coated tissue culture plate for
further diﬀerentiation, and within a few days after plating,
contracting outgrowths with cardiomyocyte characteristics
can be observed [10]. As for human iPS cells, cardiomyocyte
induction using embryoid body method was reported for
the first time in 2009 [12]. The spontaneous diﬀerentiation
of cardiomyocytes from pluripotent stem cells in embryoid
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bodies is considered to be rather ineﬃcient usually under
10% and is highly cell line dependent [6].
Cardiomyocyte induction in the embryoid body-based
diﬀerentiation system has also proven quite variable partly
due to the heterogeneity among the aggregates that may,
for example, diﬀer in size and morphology. One strategy
to address this issue was by adoption of the hanging drop
method generally used with mESC [61]. However, this
method has not been very successful with hESCs regardless
of more consistency in the embryoid body formation. As an
alternative, the forced-aggregation method was introduced,
in which a defined number of dissociated hESCs were
centrifuged into a round-bottomed ultra-low attachment 96-
well plate which allowed for better control of the embryoid
body size [62]. Although this method was quite reproducible,
as well as considered fairly practical and eﬃcient, the
forced-aggregation method was not originally developed for
cardiomyocyte diﬀerentiation [62].
At that time when embryoid body cardiac diﬀerentiation
method was introduced, limited information regarding the
mechanisms underlying cardiogenesis in human pluripotent
stem cells was available. Later, it has become evident that the
diﬀerentiation process can be manipulated by the addition of
growth factors, morphogenes, or by transgenic modifications
to direct the pluripotent stem cells toward the cardiac
cell fate. Spontaneous diﬀerentiation of hESCs, cultured
as aggregates or embryoid bodies, has been shown to be
enhanced by demethylating agent 5-aza-deoxycytidine [61].
By using the embryoid body cardiac diﬀerentiation method
with 5-aza-deoxycutidine, between 8% and 70% of the
embryoid bodies showed beating areas, and 2% to 70% of the
beating areas consisted of cardiomyocytes [61]. Low oxygen
tension has been shown to increase the number of cardiomy-
ocytes from hESCs in bioreactors. Cardiac diﬀerentiation
at 4% oxygen increases the total cell number by 30%–47%
as well as some cardiac markers when compared with 20%
oxygen [63]. Electrical stimulation with EB diﬀerentiation
method has also been shown to enhance cardiac diﬀer-
entiation of hESCs through mechanisms associated with
the intracellular generation of ROS [64]. Although many
other approaches have been used to generate cardiomyocytes
from pluripotent stem cells, the embryoid body formation
in suspension cultures remains widely applied method to
induce cardiomyocyte diﬀerentiation largely due to its simple
and inexpensive nature.
3.2. Coculture of Pluripotent Stem Cells with Cardioinductive
Cell Types. Another approach for cardiac diﬀerentiation was
inspired by developmental studies indicating the critical
role of anterior endoderm in the cardiac induction of
adjacent mesodermal structures [65–67] and has been widely
applied to induce cardiomyocyte diﬀerentiation in vitro.
The method is based on coculture of pluripotent stem cells
with a visceral endoderm-like cell line (END-2), derived
from mouse P19 embryonal carcinoma (EC) cells, which
results in the formation of beating clusters of cells that also
display characteristics of cardiomyocytes [9, 68]. The cardiac
diﬀerentiation eﬃciency of the method can be enhanced
in the absence of serum and with ascorbic acid. Ascorbic
acid has been shown to upregulate late-stage markers of
cardiogenesis [69]. Others as well as our group has found
that this diﬀerentiation method works comparably well with
iPS cell lines [70]. An END-2 conditioned media (END-2-
CM) system has also been demonstrated to induce robust
diﬀerentiation of cardiomyocytes in hESC-derived embry-
oid bodies [71–73]. Cardiomyocyte diﬀerentiation from
pluripotent stem cells occurs within 12 days of co-culture
with END-2 cells. Based on cardiomyocyte phenotype and
electrophysiology, the majority of pluripotent stem cell-
derived cardiomyocytes resemble human fetal ventricular
cardiomyocytes [9]. However, the cardiac diﬀerentiation
eﬃciency from standard END-2 co-culture experiments is
usually fairly low.
Based on the knowledge from developmental biology,
the cardioinductive signals are thought to originate from
direct cell to cell contact and/or secreted factors from the
END-2 cells which stimulate the presence of embryonic
endoderm [71]. Although the exact mechanism of END-
2 cardiac induction is still unclear, the transcriptome and
secretome of END-2 cells have been described [74, 75].
Cardiac induction by END-2-CM can be at least partly
mimicked by insulin depletion [72], inhibition of p38MAPK
[66], and addition of prostaglandin E [73]. END-2 cells
have been shown to clear insulin from the medium and to
secrete more PGI2 than any other type of mouse cells which
lack the cardiac inductive eﬀect [72, 73]. Interestingly high
concentrations of insulin appear to favor diﬀerentiation to
neuroectoderm, and blocking p38 MAPK further enhances
cardiac diﬀerentiation [71]. p38 MAPK signaling has been
found to be highly active for the neuroectoderm formation
and to be inhibitor of cardiomyogenesis, and thus blocking
of this pathway may favor meso/endoderm diﬀerentiation
[71]. These modifications to the END-2 co-culture protocol
have been reported to result in preparations of 20%–25%
cardiomyocytes. Identifying further cardiomyocyte inducing
factors from the END-2 cells may provide opportunities to
develop defined and more eﬃcient process of diﬀerentiation
for the induction of stem cells to cardiomyocytes and cardiac
progenitors. Recently, a method for inducing maturation by
replating the cardiomyocytes initially diﬀerentiated in co-
culture with END-2 cells on to fresh END-2 cells followed
by a short three-dimensional culturing step was described
[76]. The method enables cardiomyocyte maintenance for
up to 1 year with increasing maturation in terms of their
electrophysiological properties as well as increase in the
number of pacemaker cells.
3.3. Guided Cardiomyocyte Diﬀerentiation with Specific Fac-
tors. The signaling pathways regulating the cardiogenesis can
be recapitulated in cell culture by the addition of specific
growth factors such as FGFs, BMPs, and Wnts. Several
studies have shown that combinations of BMP4, Wnt3a
and Activin A induce gastrulation-like events and meso-
/endoderm development in pluripotent stem cells [77–79].
At least a part of the cardioinductive activity of anterior
endoderm is mediated by growth factors belonging to the
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TGFβ-superfamily [80, 81], and a guided cardiac diﬀeren-
tiation involving two TGFβ-family members, Activin A and
BMP4, has been described [27]. In this approach, based on a
high-density monolayer, pluripotent stem cells are cultured
in a feeder cell-free system and cardiomyocyte diﬀerentiation
is induced by a defined serum-free medium, supplemented
sequentially with BMP4 and Activin A. The growth factors
are then removed, and the cells are maintained in serum-
free medium for an additional 2-3 weeks in the absence of
exogenous growth factors. Spontaneously contracting areas
are generally observed approximately 10 days after induction
with Activin A, and enzymatically dissociated preparations
at three weeks after induction typically consist of >30%
cardiomyocytes [27]. Both hESCs and iPS cells have been
diﬀerentiated to cardiomyocytes by using this approach [17,
27].
Another protocol also involves TGFβ-family molecules
but also exploits the important roles of canonicalWnt signal-
ing in cardiogenesis. Canonical Wnt signaling exerts stage-
dependent eﬀects on cardiac diﬀerentiation: it is required
for mesoderm induction but must be inhibited later for
the induction of precardiac mesoderm [55, 56]. Based on
this information, a guided embryoid body diﬀerentiation
protocol was developed involving induction of a primitive
streak-like population in addition to formation of cardiac
mesoderm with Activin A, BMP4, bFGF, and VEGF followed
by cardiac specification with the Wnt inhibitor, Dkk-1 [57].
This protocol has been described to produce populations
consisting of ∼40%–50% cardiomyocytes. The protocol was
further enhanced by sorting the diﬀerentiating cultures for
an early cardiovascular progenitor based on expression of
the Flk-1 (also known as KDR). The early diﬀerentiating
embryoid bodies include two KDR+ populations: an early
hemangioblast population (i.e., hematopoietic and endothe-
lial progenitors) and another multipotent cardiovascular
progenitor population that can be distinguished at 5-6 days
after induction based on their diﬀerential expression of
KDR and the stem cell marker c-kit [82]. In particular,
if KDRhigh/c-kit+ cardiovascular progenitors are selected by
fluorescence-activated cell sorting (FACS) at this timepoint
and then replated in monolayer cultures, they subsequently
diﬀerentiate into highly enriched preparation of cardiomy-
ocytes, endothelial cells, and smooth muscle cells. Mesendo-
derm formation has also been induced by Wnt3A, an
activator of the canonicalWnt/β catenin signaling pathway in
cardiac diﬀerentiation protocol [60]. In this protocol, hESCs
were transiently treated with Wnt3A or BMP4, in the initial
steps of embryoid body formation, and then subsequently
decreased the amounts of serum and insulin in the culture
medium [60].
Another recent report described the cardiac diﬀeren-
tiation of pluripotent stem cells with BMP2, acting in a
combinatorial manner with Wnt3, whose expression was
triggered by the morphogen, to drive pluripotent stem
cells toward an early mesodermal and cardiogenic fate
in vitro. BMP2-induced Oct-4+ and SSEA-1+ cells give rise
to endo/mesendodermal cells secreting cardiogenic factors,
further directing the cell fate toward a cardiac phenotype
when plated on MEFs releasing bFGF [5]. The addition of
PDGF or VEGF to BMP2-induced SSEA-1+ cells cultured on
MEFs further directs the fate of the cells toward a smooth
muscle and endothelial phenotype.
Chemical biology oﬀers alternativemeans for discovering
novel cellular signaling molecules mediating pluripotent
stem cell cardiogenesis. As a consequence, high-throughput
molecular screening technology has been exploited to search
for compounds with the potential to induce cardiomyo-
genesis in vitro. To date, a few studies have published
results from such screening approaches, describing the
identification of novel small molecules that appear to
stimulate the generation of cardiomyocytes from pluripotent
stem cells, including cardiogenols, ascorbic acid, isoxazolyl-
serines, sulfonyl hydrazones, and DMSO [69]. All of these
molecules were identified based on their ability to upregulate
late-stage markers of cardiogenesis. While some clearly have
many eﬀects on cells such as DMSO and ascorbic acid, others
are probably more selective. Whether these factors have
direct role in cardiogenesis or if they stimulate certain other
cell populations which in turn activate cardiac development
remains to be determined.
3.4. Cardiac Progenitor Cells. A growing evidence suggest
that all three major cardiac cell lineages may arise from a
common multipotent cardiovascular progenitor cell popu-
lation originating in primitive streak and displaying specific
expression of markers such as Flk-1, c-kit, and Isl-1 [5, 57,
82–84]. These cardiovascular progenitor cells have recently
also been identified in early pluripotent stem cell derivatives
[5, 57]. Due to their proliferative capacity in culture, these
cell populations would be ideal for upscaling in vitro.
Furthermore, these early cardiac restricted precursor cells
would allow for the establishment of progenitor cell based in
vitro models for uncovering the early events of cardiogenesis.
Strategies that might improve cardiomyocyte yields through
stimulation of proliferation of committed progenitors might
also be valuable. Information in regard to the signals that
stimulate the replication of committed progenitors is still
lacking; however, activation of canonical Wnt signaling has
been demonstrated to expand the pool of Nkx2.5+, and Isl1+
early cardiac progenitors [39, 54, 60, 85], and the activation
of the Notch pathway in immature cardiomyocytes has been
shown to prolong their period of replicative competence [86,
87]. Other suggested mediators that might hold committed
progenitors in a proliferative state are the GSK-3 inhibitor
BIO [88], p38 MAPK inhibition [89], and the PI3K/Akt
pathway [90].
4. Enrichment Strategies of Stem
Cell-Derived Cardiomyocytes
Despite the tremendous progress in the development of
current cardiac diﬀerentiation protocols, none of the cur-
rently available protocols results in homogenous populations
of cardiomyocytes. One of the challenges over the last
years has been to develop robust isolation techniques that
allow scalable purification of cardiomyocytes and specific
cardiac subtypes. The most straightforward approach is
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mechanical isolation based on manual dissection of the
spontaneously contracting cardiac cells. The microdissected
cells from even relatively low-purity cell population can
include up to 70% cardiomyocytes [6, 9, 24]. Another fairly
exploited approach presenting significant improvements to
the enrichment process is Percoll density gradient cen-
trifugation, which takes advantage of the unique buoyant
properties of cardiomyocytes. Percoll centrifugation can
result in a three- to sevenfold enrichment of cardiomyocytes
and has been applied for enzymatically dispersed cells from
embryoid bodies and for guided diﬀerentiation protocols
[7, 22, 27, 77]. However, these enrichment protocols have
disadvantages in regard to insuﬃcient purity, fairly labor
intensive procedure, and lack of scalability.
A recent study utilized an endogenously expressed
surface marker, ALCAM, to isolate cardiomyocytes from a
mixed population of diﬀerentiated cells [78]. This approach,
however, has proven rather challenging for purifying car-
diomyocytes from pluripotent stem cells due to the limita-
tion of available cardiomyocyte-specific cell-surface markers.
Another recent study demonstrated that a fluorescent dye
labeling mitochondria could be used to selectively mark
human pluripotent stem cell-derived cardiomyocytes and,
subsequently, utilized in the enrichment of cardiomyocytes
(>99% purity) by fluorescence-activated cell sorting [91].
Other recent reports have demonstrated the guided diﬀer-
entiation and subsequent isolation of an early population
of cardiovascular progenitors, expressing Oct4, SSEA-1, and
Mesp1. The isolation of the progenitors was based on cell
sorting using an anti-SSEA-1 antibody allowing separation of
cells expressing mRNAs and proteins encoding mesodermal
and cardiac markers [5, 92].
To date, the highest levels of cardiac purity have been
obtained using genetic selection techniques. In this strat-
egy, undiﬀerentiated pluripotent stem cells are genetically
modified to carry either a reporter gene, usually a green
fluorescence protein (EGFP) or mammalian selection gene
(e.g., antibiotic resistance) under the transcriptional control
of a cardiac-specific promoter. The transgenic cells are then
induced to diﬀerentiate and selected based on activation of
the cardiac-specific promoter. While the major disadvantage
of this approach is that it entails the usual risks of genetic
modification (e.g., insertional oncogenesis), it is capable of
a significant degree of cardiac enrichment [79, 93]. Genetic
selection based on activation of either the human α-MHC
[94, 95] or MLC2v [96, 97] promoters has been shown to
generate populations of >90% human pluripotent stem cell-
derived cardiomyocytes. To sum up, most of the recently
published cardiomyocyte enrichment studies demonstrate
the advantages of using the transgenic strategy based on
cardiac-specific drug resistance selection, either alone or in
a combination with the reporter gene approach [73, 98, 99].
The influence of other cell types on cardiac diﬀerentiation is
one aspect still to be further studied to determine at which
state purification would be optimal [100]. While generally
considered useful for in vitro applications, improvements
and/or alternative strategies need to be developed to over-
come the additional hurdles before introducing genetically
modified cells into clinical cell therapy.
5. Characteristics of Pluripotent Stem
Cell-Derived Cardiomyocytes
During recent years, a number of published studies have
described the basic characteristics of pluripotent stem
cell-derived cardiomyocytes. In these reports, cell analysis
has been based on the expression of specific molecular
markers for cardiomyocytes, structural architechture, and
functionality. Although substantial heterogeneity has been
reported, in general, 30%–60% of the cells in isolated beating
areas display markers and other features of cardiomyocytes
[6, 101–103]. Pluripotent stem cell-derived cardiomyocytes
usually have less defined rod shape compared to their
mature adult counterparts. In addition, pluripotent stem
cell-derived cardiomyocytes display multinucleation at a
very limited frequency (<1%) [101] compared to adult
human cardiomyocytes (20%). At the ultrastructure level
pluripotent stem cell-derived cardiomyocytes show clearly
idenfiable sarcomeres with A, I, and Z bands and intercalated
discs with gap juctions and desmosomes, and these cells
share similarities with adult cardiomyocytes although the
myofibrillar and sarcomeric organization indicate an imma-
ture phenotype in the stem cell-derived population [6, 61,
101, 102]. In the vicinity of the sarcomeres, mitochonrdia are
also present.
On a molecular level, several markers expressed by
cardiomyocytes are also expressed by pluripotent stem
cell-derived cardiomyocytes, including transcription fac-
tors, structural proteins, hormones, ion-channels, and tight
junction proteins [6–9, 61, 67, 103]. Expression of early
cardiac-specific transcription factors involved in cardiogen-
esis such as GATA-4, Nkx2.5, Isl-1, Tbx-5, Tbx-20, and
Mef2c is generally observed also in the pluripotent stem
cell-derived cardiomyocytes [6, 7, 61, 67, 103]. In addition
to structural proteins including sarcomeric proteins α-
actinin, cardiac troponins T, and I, sarcomere myosin heavy
chain (MHC), atrial- and ventricular myosin light chains
(MLC-2A and MLC-2V), desmin, and tropomyosin, gap
junction proteins are also expressed [7–9]. The presence
of other cardiac and muscle-specific proteins including
atrial natriuretic peptide (ANP), creatine kinase-MB, and
myoglobin has also been described in several reports [7,
104]. Troponin complex is located on the thin filament
of striated muscles and regulates muscle contraction in
response to alterations in intracellular calcium ion concen-
trations.
More important, however, are the functional charac-
teristics of the cells, and diﬀerent pharmacological and
electrophysiological approaches have been used to exam-
ine these properties. As in mature cardiomyocytes, the
trigger for contraction in pluripotent stem cell-derived
cardiomyocytes is a rise in intracellular calcium [9, 105].
However, the regulation of intracellular calcium handling
has been shown to diﬀer between pluripotent stem cell-
derived cardiomyocytes and mature adult cardiomyocytes,
most likely due to the apparently immature sarcoplasmic
reticulum which has been suggested to be caused by
lack of expression of phospholamban and calsequestrin,
which are two of the main intracellular calcium handling
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proteins [105–107]. One major advantage of cardiomyocytes
derived from pluripotent stem cells is that they can be
maintained in culture for extended time periods even
months without losing their spontaneous contractile capac-
ity. Although pluripotent stem cell-derived cardiomyocytes
show unambiguous cardiac-type action potentials (AP),
these cells exhibit comparatively immature AP parameters
such as automaticity, a slower AP upstroke, and a rela-
tively depolarized maximum diastolic potential [8, 108].
Several studies have demonstrated that pluripotent stem
cell-derived cardiomyocytes exhibit spontaneous contrac-
tile activity that could be modulated by drugs such as
isoproterenol and carbachol, and thus these cells respond
to alpha/beta-adrenergic- and muscarinic stimuli further
indicating that the cells express specific surface membrane
receptors coupled to a signaling pathway that activate ion
channels, membrane transporters, and myofilament proteins
[6, 7, 103]. In contrast to a typical mature cardiomyocyte
characteristic increase in contraction amplitude in response
to increased stimulation in the (i.e., the force-frequency
relation) in the adult myocardium, pluripotent stem cell-
derived cardiomyocytes have been reported to respond in
the opposite manner and display negative force-frequency
relations [104].
In general, cardiomyocyte induction from pluripo-
tent stem cells results in mixtures of ventricular-like,
atrial-like, and pacemaker-like cells defined by intracellu-
lar electrophysiological measurements of action potentials
(APs). As shown in voltage-clamp studies, pluripotent
stem cell-derived cardiomyocytes exhibit expected ionic
currents, such as fast sodium current, L-type calcium
current, pacemaker currents, as well as transient outward
and inward rectifier potassium currents [9, 108] Interest-
ingly, diﬀerent diﬀerentiation protocols seem to aﬀect the
ratios of these cardiac cell types. While most diﬀerenti-
ation protocols based on embryoid bodies/cell aggregates
result in more or less equal numbers of ventricular- and
atrial-like cells, cardiac induction by END-2 co-culture
generally results in cell population where the majority
of the cardiomyocytes display ventricular-like phenotype
based onmorphological and electrophysiological parameters
[9].
In summary, based on the gene expression profile and
the structural-, electrophysiological-, and pharmacological
properties of the pluripotent stem cell-derived cardiomy-
ocytes they possess immature phenotype and appear to
have an immature sarcoplasmic reticulum function. The
cardiac phenotype of iPS cell-derived cardiomyocytes seems
to be comparable to that of hESC-derived cardiomyocytes
[17]. Pluripotent stem cell-derived cardiomyocytes have been
shown to mature over time in culture but without carrying
through to full maturity. Thus, additional research is needed
to find novel strategies to mature pluripotent stem cell-
derived cardiomyocytes in vitro. Nevertheless, even if some
functional properties of pluripotent stem cell-derived car-
diomyocytes apparently diﬀer from the mature cells present
in adult myocardium the in vitro generated cardiomyocytes
have a basal functionality and can still provide a useful model
for molecular cardiology.
6. Conclusion and Future Perspectives
Cardiac diﬀerentiation is a dynamic process consisting of
complex signaling network, and although various signaling
pathways and growth factors have been implicated in the
development of specialized cardiac subtypes, only limited
information about the mechanisms underlaying cardiogen-
esis in human pluripotent stem cells is currently available.
Thus, the diﬀerentiation of pluripotent stem cells toward
cardiomyocytes is still poorly defined compared with the
other cell fates. A number of diﬀerentiation protocols have
been described to generate cardiomyocytes from pluripotent
stem cells. Collectively, various cardiac diﬀerentiation studies
demonstrate how the exposure of various growth factors
to pluripotent stem cells, at an accurate timing and dose,
is essential for directing the diﬀerentiation process from
early mesendoderm via mesoderm towards a more specific
cardiac fate. Despite the recent advances in the cardiac
diﬀerentiation protocols, in most settings the cardiomyocyte
diﬀerentiation is uncontrolled and ineﬃcient remaining
less than 10% [69]. Most of the iPS cell lines generated
to date are subject to viral integration that may have
an impact on the cardiogenesis of these cells. However,
human iPS cells appear to have a cardiac potential highly
comparable to hESCs, and iPS cells can be diﬀerentiated
into cardiomyocytes using similar diﬀerentiation protocols
[17]. Based on the variations of the protocols used and
the eﬃciency at which pluripotent stem cells diﬀerentiate
to cardiomyocytes, it appears that pluripotent stem cell
lines including both hESC and iPS cell lines behave quite
diﬀerently, implicating that the specific pluripotent stem
cell line utilized might aﬀect the final result. Thus, each
pluripotent cell line may require a specific diﬀerentiation
protocol for eﬃcient induction of cardiogenesis further
complicating the overall assignment. Evidently, a more in-
depth understanding of these mechanisms will improve the
yields of pluripotent stem cell-derived cardiomyocytes for
large-scale and clinical application.
The stem cell-derived cardiomyocytes described to date,
generally resemble fetal cardiomyocytes exhibiting immature
functional and structural characteristics compared to adult
cardiomyocytes and mature only slowly in cell culture.
Furthermore, the diﬀerentiated cells are mixed populations
of noncardiac cells and cardiomyocytes with several subtypes
(e.g., ventricular-, atrial-, and nodal type) and maturation
stages. Currently, we are also lacking eﬃcient ways to guide
the cardiac subtype diﬀerentiation as well as to isolate
cardiomyocytes and subtypes of cardiomyocytes from the
heterogeneous pool of diﬀerentiating cells. Thus, eﬃcient
enrichment strategies for cardiomyocytes as well as diﬀerent
cardiac sub-types are urgently needed. A recent study
provided a strategy for the enrichment of cardiomyocytes
and in particular, the generation of a specific subtype of
cardiomyocytes, nodal-like cells, without genetic modifica-
tion. They utilized the activator of Ca2+-activated potassium
channels of small and intermediate conductance (SKCas)
on embryonic stem cells leading to induction of cardiac
mesoderm and cardiomyocyte specification resulting in a
strong enrichment of pacemaker-like cells [109].
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Most of the current cardiac diﬀerentiation methods pro-
duce beating aggregates, but for many purposes, monolayer
cardiac diﬀerentiation would be optimal. However, it has
been shown that cell-to-cell interactions in the embryoid
body and aggregate structures stimulate the expression of
markers for mesendoderm and early cardiac cell lineages,
which argues in favor of the three-dimensional cell aggre-
gates for optimal pluripotent stem cell diﬀerentiation to
cardiac myocytes [60]. Nevertheless, the current diﬀerenti-
ation protocols produce cardiomyocytes that possess many
promising capabilities and have wide-spread utility for basic
research as well as pharmaceutical industry. In future, stem
cell-derived cardiomyocytes are anticipated to have an enor-
mous impact on the treatment of heart disease. The ability
to induce iPS cells has raised the possibility to reprogram
somatic cells to an alternative diﬀerentiated fate without first
becoming a stem cell. Recently, it was shown that a com-
bination of three transcription factors (Gata4, Mef2c, and
Tbx5) reprogrammed cardiac or dermal fibroblasts directly
into spontaneously contracting cardiomyocytes, expressing
cardiac-specific markers [110]. These induced cardiomy-
ocytes oﬀer another important option to research, drug dis-
covery and cell therapy towards cardiovascular regeneration.
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